- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- 89Zr-DFO-girentuximab
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years to 99 Years
- U.S. locations
- 22
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Clear Cell Renal Cell Carcinoma, Kidney Cancer, Advanced Renal Cell Carcinoma
- Interventions
- 177Lu-labeled-girentuximab, Nivolumab, 89Zr-girentuximab PET/CT, 177Lu whole body (WB) planar and SPECT/CT scans
- Drug · Diagnostic Test
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Advanced Cancer, Clear Cell Renal Cell Carcinoma
- Interventions
- 177Lu girentuximab, Nivolumab, Cabozantinib, ArabinoFuranosylGuanine [18F]F-AraG
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Clear Cell Renal Cell Carcinoma
- Interventions
- Belzutifan, 89Zr-DFO-girentuximab, 89Zr-DFO-girentuximab PET
- Drug · Device
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Clear Cell Renal Cell Carcinoma
- Interventions
- 89Zr-girentuximab
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • Atlanta, Georgia + 6 more
- Conditions
- Kidney Cancer
- Interventions
- motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC
- Interventions
- 89Zr-Girentuximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, Zirconium Zr 89 Girentuximab
- Procedure · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme, Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Epithelial Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Soft Tissue Sarcoma, Gastric Adenocarcinoma, Malignant Mesothelioma (MM), Von Hippel Lindau, Bladder Cancer, Bladder Urothelial Carcinoma
- Interventions
- 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
- Industry
- Eligibility
- 18 Years to 95 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 7 more
- Conditions
- Kidney Cancer
- Interventions
- girentuximab, placebo
- Biological · Other
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 39
- States / cities
- Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Iodine (124I) Girentuximab
- Drug
- Lead sponsor
- Heidelberg Pharma AG
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Tampa, Florida • Burlington, Massachusetts + 5 more